Before the $625MN dollar deal can happen, injectible drug-maker Claris must divest from two specific pharmaceutical products; fluconazole in saline intravenous bags used for fungal treatments, and milrinone in dextrose intravenous bags, which are used for congestive heart failure. The rights to these products must be given to NJ-based pharma company Renaissance Lakewood LLC, as the FTC believes their continued use by Claris would greatly reduce competition in the market.
You can read the full final order from the FTC here.
© New Kapitall Holdings LLC. All rights reserved. Kapitall Wire is a division of New Kapitall Holdings LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings LLC. Kapitall Wire, which is not a broker/dealer, offers free cutting edge content and commentary and is produced for informational purposes only and should not be construed as research. Kapitall Wire is a product offered by New Kapitall Holdings, however, KapGen compliance personnel will oversee all Kapitall Wire material prior to release.